Life sciences, Current


BioCaptiva has developed BIOCAPTOR, a medical device that captures cfDNA.

Prototype testing shows that the device has the potential to greatly enhance detection of early-stage cancers in patients without the need for surgical biopsy. It could also pave the way for new approaches to disease monitoring, resulting in better outcomes for patients.

BIOCAPTOR works alongside a standard apheresis machine, filtering cfDNA (circulating free DNA) from the patient’s blood system. It captures cfDNA in much greater quantities than the current standard of a single blood draw. It can therefore overcome a significant current limitation of cancer liquid biopsy testing.

Year of investment



Sarah Hardy

Seeking investment?

Our team is always actively seeking new investment opportunities. They review circa 200 business plans each year.

Become a member

Our members are genuinely motivated to give something back and build great businesses in Scotland, as well as making a financial return.

We use cookies to give you the best experience. Cookie Policy

Preloader image